Quebec platelet disorder

Expert Review of Hematology

Volumn 4, Issue 2, 2011, Pages 137-141

  Hayward, Catherine Pm ^a   Rivard, Georges E ^b  

^a MCMASTER UNIVERSITY   (Canada)

^b UNIVERSITY OF MONTREAL   (Canada)

Author keywords

fibrinolytic disorders; inherited platelet disorders; platelet function; Quebec platelet disorder; urokinase plasminogen activator

Indexed keywords

BLOOD CLOTTING FACTOR 5; PLAU PROTEIN; PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; BLEEDING DISORDER; BLOOD CLOTTING; CANADA; CELL CULTURE; CHROMOSOME 10; FIBRINOLYSIS; GENE DUPLICATION; GENE EXPRESSION; GENE MUTATION; GENETICS; HUMAN; LABORATORY TEST; MEGAKARYOCYTE; NONHUMAN; PRIORITY JOURNAL; THROMBOCYTE COUNT; THROMBOCYTE DISORDER; WESTERN BLOTTING;

ANIMALS; DISEASE MODELS, ANIMAL; FACTOR V DEFICIENCY; GENE DOSAGE; HEMORRHAGE; HUMANS; MICE; MICE, TRANSGENIC; MUTATION; THROMBOPOIESIS; UROKINASE-TYPE PLASMINOGEN ACTIVATOR;

EID: 79955055859     PISSN: 17474086     EISSN: None     Source Type: Journal    
DOI: 10.1586/ehm.11.5     Document Type: Article

References (21)

1. McKay H, Derome F, Haq MA et al. Bleeding risks associated with inheritance of the Quebec platelet disorder. Blood 104(1), 159-165 (2004). (Pubitemid 38879852)
2. Diamandis M, Paterson AD, Rommens JM et al. Quebec platelet disorder is linked to the urokinase plasminogen activator gene (PLAU) and increases expression of the linked allele in megakaryocytes. Blood 113(7), 1543-1546 (2009).
3. Paterson AD, Rommens JM, Bharaj B et al. Persons with Quebec platelet disorder have a tandem duplication of PLAU, the urokinase plasminogen activator gene. Blood 115(6), 1264-1266 (2010).
4. Hayward CP, Rivard GE, Kane WH et al. An autosomal dominant, qualitative platelet disorder associated with multimerin deficiency, abnormalities in platelet factor V, thrombospondin, von Willebrand factor, and fibrinogen and an epinephrine aggregation defect. Blood 87(12), 4967-4978 (1996).
5. Diamandis M, Veljkovic DK, Maurer-Spurej E, Rivard GE, Hayward CP. Quebec platelet disorder: features, pathogenesis and treatment. Blood Coagul. Fibrinolysis 19(2), 109-119 (2008). (Pubitemid 351252988)
6. Tracy PB, Giles AR, Mann KG, Eide LL, Hoogendoorn H, Rivard GE. Factor V (Quebec): a bleeding diathesis associated with a qualitative platelet factor V deficiency. J. Clin. Invest. 74(4), 1221-1228 (1984). (Pubitemid 15206817)
7. Hayward CP, Cramer EM, Kane WH et al. Studies of a second family with the Quebec platelet disorder: evidence that the degradation of the a-granule membrane and its soluble contents are not secondary to a defect in targeting proteins to a-granules. Blood 89(4), 1243-1253 (1997). (Pubitemid 27079988)
8. Janeway CM, Rivard GE, Tracy PB, Mann KG. Factor V Quebec revisited. Blood 87(9), 3571-3578 (1996). (Pubitemid 26129583)
9. Kahr WH, Zheng S, Sheth PM et al. Platelets from patients with the Quebec platelet disorder contain and secrete abnormal amounts of urokinase-type plasminogen activator. Blood 98(2), 257-265 (2001).
10. Sheth PM, Kahr WH, Haq MA, Veljkovic DK, Rivard GE, Hayward CP. Intracellular activation of the fibrinolytic cascade in the Quebec platelet disorder. Thromb. Haemost. 90(2), 293-298 (2003). (Pubitemid 36992505)
11. Diamandis M, Adam F, Kahr WH et al. Insights into abnormal hemostasis in the Quebec platelet disorder from analyses of clot lysis. J. Thromb. Haemost. 4(5), 1086-1094 (2006).
12. Diamandis M, Veljkovic DK, Derome F, Rivard GE, Hayward CP. Evaluation of urokinase plasminogen activator in urine from individuals with Quebec platelet disorder. Blood Coagul. Fibrinolysis 19(5), 463-464 (2008).
13. Veljkovic DK, Rivard GE, Diamandis M, Cramer-Borde EM, Rivard GE, Hayward CP. Increased expression of urokinase plasminogen activator in Quebec platelet disorder is linked to megakaryocyte differentiation. Blood 113(7), 1535-1542 (2009).
14. Weiss HJ, Lages B, Zheng S, Hayward CP. Platelet factor V New York: a defect in factor V distinct from that in factor V Quebec resulting in impaired prothrombinase generation. Am. J. Hematol. 66(2), 130-139 (2001). (Pubitemid 32096628)
15. Hayward CP, Welch B, Bouchard M, Zheng S, Rivard GE. Fibrinogen degradation products in patients with the Quebec platelet disorder. Br. J. Haematol. 97(2), 497-503 (1997). (Pubitemid 27224639)
16. Weiss HJ. Impaired platelet procoagulant mechanisms in patients with bleeding disorders. Semin. Thromb. Hemost. 35(2), 233-241 (2009).
17. Hayward CP, Pai M, Liu Y et al. Diagnostic utility of light transmission platelet aggregometry: results from a prospective study of individuals referredfor bleeding disorder assessments. J. Thromb. Haemost. 7(4), 676-684 (2009).
18. Hayward CP. Diagnostic approach to platelet function disorders. Transfus. Apher. Sci. 38(1), 65-76 (2008).
19. Kufrin D, Eslin DE, Bdeir K et al. Antithrombotic thrombocytes: ectopic expression of urokinase-type plasminogen activator in platelets. Blood 102(3), 926-933 (2003). (Pubitemid 36917785)
20. Abbasi AH, Shaikh Q, Hussain SA. Quebec platelet disorder. J. Coll. Physicians Surg. Pak. 20(8), 549-550 (2010).
21. Hayward CP, Rao AK, Cattaneo M. Congenital platelet disorders: overview of their mechanisms, diagnostic evaluation and treatment. Haemophilia 12(Suppl. 3), 128-136 (2006).